News
FDA approves Dupixent to treat children with atopic dermatitis. Sanofi + REgeneron
The FDA approved Dupixent (dupilumab) from Sanofi + Regeneron for children aged 6 to 11 years with moderate-to-severe atopic dermatitis whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable. Dupixent is the only biologic medicine approved for this patient population.
Condition: Atopic Dermatitis (Eczema)
Type: drug
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
2 mins